Nurix Therapeutics NRIX
NASDAQ NRIX
$16.32 +0.44 (+2.77%)
As of: Nov 11, 2026 · 3:59 PM EST

Nurix Therapeutics (NRIX) Cash from Financing Activities (2019 - 2026)

Updated

Nurix Therapeutics (NRIX) recorded Cash from Financing Activities of $5.16 million in fiscal Q3 2026 (quarter ended Aug 31, 2026), up 346.7% from $1.16 million a year earlier.

Analysis

Nurix Therapeutics (NRIX) Cash from Financing Activities (2019 - 2026) Analysis & Trends

On a TTM basis, Nurix Therapeutics' Cash from Financing Activities came in at $261.21 million as of Aug 31, 2026, up 28.6% year-over-year; for FY2025 (ended Nov 30, 2025), it came in at $238.64 million, down 50.9% from FY2024.

  • Annual Cash from Financing Activities has a five-year compound annual growth rate of -6.8% (FY2020 to FY2025).
  • Across earlier fiscal years, Cash from Financing Activities came in at $485.67 million in FY2024, $3.22 million in FY2023 (-97.3%), $117.19 million in FY2022 (-23.8%) and $153.88 million in FY2021 (-54.6%).
  • Quarterly Cash from Financing Activities has ranged from -$135,000 in fiscal Q4 2022 to $237.75 million in fiscal Q2 2024 over the past five years.
  • On a year-over-year basis, Cash from Financing Activities rose in two of the last five quarters, with growth averaging 31.5%.
  • Peak year-over-year performance for Cash from Financing Activities in the last five years was growth of 346.7% in fiscal Q3 2026, against a decline of 100.0% in fiscal Q2 2025 at the low end.
  • Per Business Quant, the preceding three fiscal quarters came in at $66,000 (Q2 2026), $19.98 million (Q1 2026) and $236.01 million (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -7.22 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -8.53 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 6.82 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -2.43 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 6.63 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -4.39 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -1.53 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -2.51 Bn
10 Nurix Therapeutics 1.73 Bn -891.35 Mn - 5.16 Mn
Historic Data

Historic Data

Download Data
DateValue
Aug 31, 2026 5.16 Mn
May 31, 2026 66,000.00
Feb 28, 2026 19.98 Mn
Nov 30, 2025 236.01 Mn
Aug 31, 2025 1.16 Mn
May 31, 2025 6,000.00
Feb 28, 2025 1.47 Mn
Nov 30, 2024 200.52 Mn
Aug 31, 2024 45.77 Mn
May 31, 2024 237.75 Mn
Feb 29, 2024 1.62 Mn
Nov 30, 2023 7,000.00
Aug 31, 2023 1.70 Mn
May 31, 2023 25,000.00
Feb 28, 2023 1.48 Mn
Nov 30, 2022 -135,000.00
Aug 31, 2022 115.41 Mn
May 31, 2022 432,000.00
Feb 28, 2022 1.49 Mn
Nov 30, 2021 500,000.00
API Access

Nurix Therapeutics Cash from Financing Activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=NRIX&period=max&api_key=YOUR_API_KEY